Why This Update Matters
In this quick, fact-focused SkinSync episode, producer Jennifer Conner, PA-C, sits down with PA Shanna Miranti to walk through the iPledge REMS changes taking effect November 15, 2026. The goal, as Miranti frames it, is a 'quick and very factual' rundown that prescribers can disseminate to their practices and colleagues before clinic that morning.
Miranti reminds listeners that iPledge has been an FDA-mandated requirement for isotretinoin prescribing since March 1, 2006. Before that, as she and Conner recall, clinicians simply 'slapped a little yellow sticker on the prescription.' For all its administrative headaches, the program exists to protect patients from isotretinoin's significant teratogenic risk and potential for severe birth defects.
What Hasn't Changed
The core purpose of the REMS program stays the same: preventing fetal exposure, ensuring informed consent and counseling, and maintaining monitoring and pregnancy testing throughout treatment. The gender-neutral patient categories introduced in 2021 also remain — patients are still designated as people who can get pregnant or people who cannot get pregnant.
Miranti stresses that prescribers must keep reviewing these categories carefully. Patients assigned female at birth who still have a uterus may fall into the 'can get pregnant' category and still require pregnancy testing. When Conner asks how to handle this with transgender patients, Miranti says she breaks it down to anatomy: 'If you still have a uterus, you still have what the FDA considers a nest,' so testing is required even when pregnancy is effectively impossible. She approaches the conversation carefully, making clear it is an FDA requirement and not a judgment. Conner adds that she frames it the same way for young, never-sexually-active patients so no one feels singled out.
Also unchanged: monthly authorization before dispensing, the maximum 30-day supply limit, and contraceptive counseling as a central component of prescribing for patients who can get pregnant.
Pregnancy Testing Now Requires a Medical Setting
Miranti flags the biggest workflow shift first. During and after COVID, iPledge allowed home pregnancy testing, sometimes even before starting treatment. As of November 15, both required pre-treatment pregnancy tests for patients who can get pregnant must now be completed in a medical setting — your office, a clinic, or a laboratory. If you have a CLIA-certified lab in your clinic, document that in your note. The two pre-treatment tests (at registration and at medication initiation) should be at least 30 days apart, and either can be urine or serum.
Monthly pregnancy tests during treatment may still allow for home testing, but only if the prescriber establishes procedures to collect results, verify authenticity, and minimize falsification or misinterpretation. Miranti recommends standardizing this within your clinic and consulting the iPledge website for guidance. Conner shares her own practice: for her scattered college-student patients across Indiana, she offers telehealth visits, has them show the test on screen, and won't send the prescription until results are uploaded to the patient portal.
Goodbye to the 19-Day Lockout
The change both hosts are most excited about: the removal of the 19-day lockout that previously followed a missed seven-day prescribing window. Miranti calls it 'the biggest change I'm excited for,' and Conner describes the old rule as a 'complete nightmare' that patients often assumed was her personal policy rather than the FDA's.
Clinically, the lockout could create a 19-day gap in therapy mid-course — long enough for the drug to clear the system when steady levels are the goal. It also created a real access barrier for patients facing socioeconomic challenges or distance to clinic. Now, a patient who misses the window can be reconfirmed right away. They will still need a repeat pregnancy test in a medical setting before restarting, but there is no additional waiting period.
Counseling, Categories, and Keeping Staff Current
Documentation for patients who cannot get pregnant has been streamlined. The confirmation counseling that used to be required monthly is now only required at initiation of therapy — including the reminder not to share the medication, even though there is no confirmed fetal risk when a father takes it. The 30-day maximum supply still applies, so monthly visits may still be necessary.
For category management, only the prescriber can now change a patient's iPledge category, and that must be done under the prescriber's own iPledge number — designees and delegates can no longer make that change. Updated educational materials also now include information and guidance on emergency contraception. Miranti advises referring patients to an OB/GYN if you aren't fully comfortable with contraceptive counseling.
Both hosts close by urging prescribers to get their clinical staff up to date, since staff often handle these conversations with patients. As Miranti puts it, be a rule follower in this one category — there's no 'iPledge jail,' but protecting your prescriber status means you can keep providing this life-changing medication to future patients.